The role of older antibiotics in the treatment of skin and soft tissue infections: current perspectives.

IF 3.6 3区医学 Q2 INFECTIOUS DISEASES Current Opinion in Infectious Diseases Pub Date : 2025-04-01 Epub Date: 2024-12-16 DOI:10.1097/QCO.0000000000001085

Fatima Allaw, Maya Dagher, Souha S Kanj

{"title":"The role of older antibiotics in the treatment of skin and soft tissue infections: current perspectives.","authors":"Fatima Allaw, Maya Dagher, Souha S Kanj","doi":"10.1097/QCO.0000000000001085","DOIUrl":null,"url":null,"abstract":"Purpose of review: The aim is to discuss the evidence and recent literature on the role of older antibiotics in the treatment of skin and soft tissue infections (SSTIs).Recent findings: The choice of therapy for SSTIs is complicated in view of the rising antimicrobial resistance (AMR) and the availability of new antibiotics. SSTIs are predominantly caused by Staphylococcus aureus and beta-hemolytic streptococci, but other organisms can be involved in patients with comorbidities or post trauma. Treatment options are dictated by the accessibility and cost of newer antibiotics in resource-constrained settings. 'Old antibiotics' including β-lactams, doxycycline, trimethoprim-sulfamethoxazole (TMP/SMX), clindamycin, azithromycin, and ciprofloxacin remain good choices in treating SSTIs. They offer affordable options for outpatient settings. Only few randomized trials have addressed the role of the old agents in SSTIs treatment. Studies suggest that these agents remain effective for empirical and targeted therapy based on the epidemiological context. Ongoing surveillance and clinical trials are needed to assess the role of these agents and to integrate them into modern SSTIs management, supporting sustainable treatment models in both high-income and low-income settings.Summary: Older antibiotics can be effectively used in treating SSTIs, provided their use is guided by current epidemiological data or culture and susceptibility results.","PeriodicalId":10880,"journal":{"name":"Current Opinion in Infectious Diseases","volume":" ","pages":"99-106"},"PeriodicalIF":3.6000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/QCO.0000000000001085","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/16 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: The aim is to discuss the evidence and recent literature on the role of older antibiotics in the treatment of skin and soft tissue infections (SSTIs).

Recent findings: The choice of therapy for SSTIs is complicated in view of the rising antimicrobial resistance (AMR) and the availability of new antibiotics. SSTIs are predominantly caused by Staphylococcus aureus and beta-hemolytic streptococci, but other organisms can be involved in patients with comorbidities or post trauma. Treatment options are dictated by the accessibility and cost of newer antibiotics in resource-constrained settings. 'Old antibiotics' including β-lactams, doxycycline, trimethoprim-sulfamethoxazole (TMP/SMX), clindamycin, azithromycin, and ciprofloxacin remain good choices in treating SSTIs. They offer affordable options for outpatient settings. Only few randomized trials have addressed the role of the old agents in SSTIs treatment. Studies suggest that these agents remain effective for empirical and targeted therapy based on the epidemiological context. Ongoing surveillance and clinical trials are needed to assess the role of these agents and to integrate them into modern SSTIs management, supporting sustainable treatment models in both high-income and low-income settings.

Summary: Older antibiotics can be effectively used in treating SSTIs, provided their use is guided by current epidemiological data or culture and susceptibility results.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

老式抗生素在治疗皮肤和软组织感染中的作用：当前视角。

综述的目的：目的是讨论旧抗生素在治疗皮肤和软组织感染（SSTIs）中的作用的证据和最新文献。最近发现：鉴于抗菌素耐药性（AMR）的上升和新抗生素的可用性，ssti的治疗选择是复杂的。SSTIs主要由金黄色葡萄球菌和溶血性链球菌引起，但其他生物也可能与合并症或创伤后患者有关。在资源有限的环境中，治疗选择取决于新抗生素的可及性和成本。“旧抗生素”包括β-内酰胺类、多西环素、甲氧苄啶-磺胺甲恶唑（TMP/SMX）、克林霉素、阿奇霉素和环丙沙星仍然是治疗性传播感染的良好选择。他们为门诊病人提供负担得起的选择。只有少数随机试验研究了旧药物在ssti治疗中的作用。研究表明，基于流行病学背景，这些药物对经验性和靶向性治疗仍然有效。需要进行持续的监测和临床试验，以评估这些药物的作用，并将其纳入现代性传播感染管理，支持高收入和低收入环境下的可持续治疗模式。总结：在当前流行病学数据或培养和药敏结果的指导下，可以有效地使用旧抗生素治疗性传播感染。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Opinion in Infectious Diseases 医学-传染病学

CiteScore

6.70

自引率

2.60%

发文量

121

审稿时长

6-12 weeks

期刊介绍： This reader-friendly, bimonthly resource provides a powerful, broad-based perspective on the most important advances from throughout the world literature. Featuring renowned guest editors and focusing exclusively on two topics, every issue of Current Opinion in Infectious Disease delivers unvarnished, expert assessments of developments from the previous year. Insightful editorials and on-the-mark invited reviews cover key subjects such as HIV infection and AIDS; skin and soft tissue infections; respiratory infections; paediatric and neonatal infections; gastrointestinal infections; tropical and travel-associated diseases; and antimicrobial agents.